Suphi Vehid
Suphi Vehid has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Asli Çurgunlu
İSTANBUL ÜNİVERSİTESİ-CERRAHPAŞA, CERRAHPAŞA TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
1 shared publication - Ayse Cigdem Tutuncu
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Anesthesiology and Reanimation, Istanbul, Turkey
1 shared publication - Aysegul Sevim Kecici
Department of Dermatology University of Medical SciencesHaydarpasa Numune Training and Research Hospital Istanbul Turkey
1 shared publication - Bekir Kocazeybek
Department of Medical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul 34320, Turkey
1 shared publication - Bernard Tahirbegolli
Department of Management of Health Institution and Services, Heimerer College, 10000 Prishtina, Kosovo
1 shared publication - Bilgul Mete
Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
1 shared publication
Latest Publications
- 27 December 2021
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 34 (3) , 211-218
The Distribution of Aerobic and Anaerobic Bacteria in the Etiology of Granulomatous Mastitis and Their Resistance to Antimicrobial Agents
GİRİŞ Mastitler, memenin inflamasyonu ile seyreden infeksiyöz ya da noninfeksiyöz hastalıklar olup genellikle kadınları etkiler (1). Mastitler; laktasyonel mastit, non-laktasyonel mastit ve meme apsesi olmak üzere üç grupta incelenmektedir. Non-laktasyonel mastit; santral veya subareolar infeksiyon, periferal infeksiyon ve granülomatöz infeksiyon olmak üzere üç gruba ayrılır (1). İnfeksiyöz olmayan mastit (non-laktasyonel mastit), memenin lobüllerinde genişleme ile […]
- 27 December 2021
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 34 (3) , 211-218
The Distribution of Aerobic and Anaerobic Bacteria in the Etiology of Granulomatous Mastitis and Their Resistance to Antimicrobial Agents
GİRİŞ Mastitler, memenin inflamasyonu ile seyreden infeksiyöz ya da noninfeksiyöz hastalıklar olup genellikle kadınları etkiler (1). Mastitler; laktasyonel mastit, non-laktasyonel mastit ve meme apsesi olmak üzere üç grupta incelenmektedir. Non-laktasyonel mastit; santral veya subareolar infeksiyon, periferal infeksiyon ve granülomatöz infeksiyon olmak üzere üç gruba ayrılır (1). İnfeksiyöz olmayan mastit (non-laktasyonel mastit), memenin lobüllerinde genişleme ile […]
- Open Access
- 15 March 2021
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 39 (2) , 161-162
Effects of Short-message Notifications on Type 2 Diabetes Management in Middle-aged Turkish Patients: A Randomized Trial
- 15 March 2021
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 39 (2) , 161-162
Open AccessEffects of Short-message Notifications on Type 2 Diabetes Management in Middle-aged Turkish Patients: A Randomized Trial
- Open Access
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1817-1824
Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata
Background and Objectives Alopecia areata is an inflammatory disease with a genetic and autoimmune basis. We aimed to study the efficacy, and safety of an immunomodulatory therapeutic agent, diphenylcyclopropenone, while manifesting the association with histopathological features, prognostic factors and side effects. Materials and Methods In this retrospective study, 98 patients (60 men, 38 women) with alopecia who were referred to the ?Hair Disease Polyclinic? at Department of Dermatology between 2011 and 2015 were included. Together with medical histories and dermatological examinations, all patients were taken a skin biopsy for histopathological examination prior to the therapy. Therapeutic success was evaluated on the basis of hair re-growth percentage. Results Regarding the overall treatment success, 33 (34%) patients had complete response, 16 (16%) patients had partial response (between 50-99%), 27 (28%) patients had minimal response (between 1-49%), and 22 (22%) patients were non-responders. Both genders were equally represented in the outcome. Conclusions There was a significant relation between the severity of alopecia and treatment outcome. (p=0.038) Patients with alopecia areata had significantly better response when compared to alopecia totalis and universalis. There was no statistically significant relation with other parameters such as disease duration, age, gender, atopy history, age of onset, and histopathological features.
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1817-1824
Open AccessAssessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata
Background and Objectives Alopecia areata is an inflammatory disease with a genetic and autoimmune basis. We aimed to study the efficacy, and safety of an immunomodulatory therapeutic agent, diphenylcyclopropenone, while manifesting the association with histopathological features, prognostic factors and side effects. Materials and Methods In this retrospective study, 98 patients (60 men, 38 women) with alopecia who were referred to the ?Hair Disease Polyclinic? at Department of Dermatology between 2011 and 2015 were included. Together with medical histories and dermatological examinations, all patients were taken a skin biopsy for histopathological examination prior to the therapy. Therapeutic success was evaluated on the basis of hair re-growth percentage. Results Regarding the overall treatment success, 33 (34%) patients had complete response, 16 (16%) patients had partial response (between 50-99%), 27 (28%) patients had minimal response (between 1-49%), and 22 (22%) patients were non-responders. Both genders were equally represented in the outcome. Conclusions There was a significant relation between the severity of alopecia and treatment outcome. (p=0.038) Patients with alopecia areata had significantly better response when compared to alopecia totalis and universalis. There was no statistically significant relation with other parameters such as disease duration, age, gender, atopy history, age of onset, and histopathological features.
- Open Access
- 1 June 2011
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 28, 150
Comparison of truview EVO2 and macintosh laryngoscopes in infants
- 1 June 2011
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 28, 150
Open AccessComparison of truview EVO2 and macintosh laryngoscopes in infants
- Open Access
- 1 January 2003
- Published by International Heart Journal (Japanese Heart Journal) in Japanese Heart Journal
- Vol. 44 (6) , 953-961
Effects of Low and High Doses of Atorvastatin on Arterial Compliance.
At the beginning of atherosclerosis before evidence of morphological lesions or plaques, vascular distensibility or arterial compliance decreased gradually. This endothelial dysfunction is regarded as an early feature of atherosclerosis. In a randomized, double-blind study design, group I (12 patients; 7 males, 5 females) with serum LDL-C levels higher than 170 mg/dL and without any other risk factor for atherosclerosis received three months of 20 mg/day atorvastatin treatment while group II (8 males, 4 females) with the same characteristics received 80 mg/day. Baseline and posttreatment serum lipid fractions and arterial compliance were measured. Arterial compliance was measured noninvasively in the left common carotid artery with color Doppler ultrasound. Atorvastatin reduced total cholesterol (TC), LDL-C, and triglyceride levels by 32% (P < 0.001), 40.8% (P < 0.001), and 19% (P < 0.001), respectively, and increased HDL-C by 6.9% (P = 0.002) in the first group. In the second group these reductions were 38.5% (P < 0.001), 46.2% (P < 0.001), and 26.78% (P < 0.001), respectively, and the increase in HDL was 7.8% (P = 0.03). It was observed that the decrease in serum TC, LDL-C and triglyceride levels were significantly higher in the second group than the first group. With atorvastatin, the distensibility coefficient (DC) and compliance coefficient (CC) increased from 18.7 ± 3.4 to 21.3 ± 2.9 10-3.kPa-1 (P < 0.001) and from 0.69 ± 0.05 to 0.77 ± 0.03 mm2.kPa-1 (P < 0.001) in the first group while they changed from 18.3 ± 3.6 to 21.9 ± 3.0 10-3.kPa-1 (P < 0.001) and from 0.70 ± 0.04 to 0.81 ± 0.01 mm2.kPa-1 (P < 0.001) respectively, in the second group. DC and CC increased in both groups, but the differences between the groups were not significant. High doses of atorvastatin reduce blood lipid levels more than conventional doses, however, the change in compliance is not dose-dependent. As endothelial dysfunction is regarded as an early feature of atherosclerosis, there would be no need to administer aggressive doses in a patient without any risk factors other than hyperlipidemia.
- 1 January 2003
- Published by International Heart Journal (Japanese Heart Journal) in Japanese Heart Journal
- Vol. 44 (6) , 953-961
Open AccessEffects of Low and High Doses of Atorvastatin on Arterial Compliance.
At the beginning of atherosclerosis before evidence of morphological lesions or plaques, vascular distensibility or arterial compliance decreased gradually. This endothelial dysfunction is regarded as an early feature of atherosclerosis. In a randomized, double-blind study design, group I (12 patients; 7 males, 5 females) with serum LDL-C levels higher than 170 mg/dL and without any other risk factor for atherosclerosis received three months of 20 mg/day atorvastatin treatment while group II (8 males, 4 females) with the same characteristics received 80 mg/day. Baseline and posttreatment serum lipid fractions and arterial compliance were measured. Arterial compliance was measured noninvasively in the left common carotid artery with color Doppler ultrasound. Atorvastatin reduced total cholesterol (TC), LDL-C, and triglyceride levels by 32% (P < 0.001), 40.8% (P < 0.001), and 19% (P < 0.001), respectively, and increased HDL-C by 6.9% (P = 0.002) in the first group. In the second group these reductions were 38.5% (P < 0.001), 46.2% (P < 0.001), and 26.78% (P < 0.001), respectively, and the increase in HDL was 7.8% (P = 0.03). It was observed that the decrease in serum TC, LDL-C and triglyceride levels were significantly higher in the second group than the first group. With atorvastatin, the distensibility coefficient (DC) and compliance coefficient (CC) increased from 18.7 ± 3.4 to 21.3 ± 2.9 10-3.kPa-1 (P < 0.001) and from 0.69 ± 0.05 to 0.77 ± 0.03 mm2.kPa-1 (P < 0.001) in the first group while they changed from 18.3 ± 3.6 to 21.9 ± 3.0 10-3.kPa-1 (P < 0.001) and from 0.70 ± 0.04 to 0.81 ± 0.01 mm2.kPa-1 (P < 0.001) respectively, in the second group. DC and CC increased in both groups, but the differences between the groups were not significant. High doses of atorvastatin reduce blood lipid levels more than conventional doses, however, the change in compliance is not dose-dependent. As endothelial dysfunction is regarded as an early feature of atherosclerosis, there would be no need to administer aggressive doses in a patient without any risk factors other than hyperlipidemia.